These findings suggested that DYRK1A was involved in elaborately disrupted regulatory networks in MEF2D fusion BCP-ALL, whereas inhibition of DYRK1A alone was insufficient to decrease MH expression. Here, DYRK1A is linked to acute lymphoblastic leukemia.